Current treatment strategies and nanoparticle-mediated drug delivery systems for pulmonary arterial hypertension

Research output: Contribution to journalReview article

Abstract

There are three critical pathways for the pathogenesis and progression of pulmonary arterial hypertension (PAH): the prostacyclin (prostaglandin I2) (PGI2), nitric oxide (NO), and endothelin pathways. The current approved drugs targeting these three pathways, including prostacyclin (PGI2), phosphodiesterase type-5 (PDE5) inhibitors, and endothelin receptor antagonists (ERAs), have been shown to be effective, however, PAH remains a severe clinical condition and the long-term survival of patients with PAH is still suboptimal. The full therapeutic abilities of available drugs are reduced by medication, patient non-compliance, and side effects. Nanoparticles are expected to address these problems by providing a novel drug delivery approach for the treatment of PAH. Drug-loaded nanoparticles for local delivery can optimize the efficacy and minimize the adverse effects of drugs. Prostacyclin (PGI2) analogue, PDE5 inhibitors, ERA, pitavastatin, imatinib, rapamycin, fasudil, and oligonucleotides-loaded nanoparticles have been reported to be effective in animal PAH models and in vitro studies. However, the efficacy and safety of nanoparticle mediated-drug delivery systems for PAH treatment in humans are unknown and further clinical studies are required to clarify these points.

Original languageEnglish
Article number5885
JournalInternational journal of molecular sciences
Volume20
Issue number23
DOIs
Publication statusPublished - Dec 1 2019

Fingerprint

hypertension
Epoprostenol
Drug Delivery Systems
Pulmonary Hypertension
Nanoparticles
delivery
drugs
prostaglandins
nanoparticles
Phosphodiesterase 5 Inhibitors
Pharmaceutical Preparations
inhibitors
Oligonucleotides
Nitric oxide
Therapeutics
Drug delivery
Synthetic Prostaglandins
pathogenesis
Animals
Aptitude

Keywords

  • Endothelin
  • Nitric oxide
  • Prostaglandin I
  • Pulmonary arterial hypertension

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

@article{f45b584076134c33bee64afc1617ec9c,
title = "Current treatment strategies and nanoparticle-mediated drug delivery systems for pulmonary arterial hypertension",
abstract = "There are three critical pathways for the pathogenesis and progression of pulmonary arterial hypertension (PAH): the prostacyclin (prostaglandin I2) (PGI2), nitric oxide (NO), and endothelin pathways. The current approved drugs targeting these three pathways, including prostacyclin (PGI2), phosphodiesterase type-5 (PDE5) inhibitors, and endothelin receptor antagonists (ERAs), have been shown to be effective, however, PAH remains a severe clinical condition and the long-term survival of patients with PAH is still suboptimal. The full therapeutic abilities of available drugs are reduced by medication, patient non-compliance, and side effects. Nanoparticles are expected to address these problems by providing a novel drug delivery approach for the treatment of PAH. Drug-loaded nanoparticles for local delivery can optimize the efficacy and minimize the adverse effects of drugs. Prostacyclin (PGI2) analogue, PDE5 inhibitors, ERA, pitavastatin, imatinib, rapamycin, fasudil, and oligonucleotides-loaded nanoparticles have been reported to be effective in animal PAH models and in vitro studies. However, the efficacy and safety of nanoparticle mediated-drug delivery systems for PAH treatment in humans are unknown and further clinical studies are required to clarify these points.",
keywords = "Endothelin, Nitric oxide, Prostaglandin I, Pulmonary arterial hypertension",
author = "Kazufumi Nakamura and Satoshi Akagi and Kentaro Ejiri and Masashi Yoshida and Toru Miyoshi and Norihisa Toh and Koji Nakagawa and Yoichi Takaya and Hiromi Matsubara and Hiroshi Ito",
year = "2019",
month = "12",
day = "1",
doi = "10.3390/ijms20235885",
language = "English",
volume = "20",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "23",

}

TY - JOUR

T1 - Current treatment strategies and nanoparticle-mediated drug delivery systems for pulmonary arterial hypertension

AU - Nakamura, Kazufumi

AU - Akagi, Satoshi

AU - Ejiri, Kentaro

AU - Yoshida, Masashi

AU - Miyoshi, Toru

AU - Toh, Norihisa

AU - Nakagawa, Koji

AU - Takaya, Yoichi

AU - Matsubara, Hiromi

AU - Ito, Hiroshi

PY - 2019/12/1

Y1 - 2019/12/1

N2 - There are three critical pathways for the pathogenesis and progression of pulmonary arterial hypertension (PAH): the prostacyclin (prostaglandin I2) (PGI2), nitric oxide (NO), and endothelin pathways. The current approved drugs targeting these three pathways, including prostacyclin (PGI2), phosphodiesterase type-5 (PDE5) inhibitors, and endothelin receptor antagonists (ERAs), have been shown to be effective, however, PAH remains a severe clinical condition and the long-term survival of patients with PAH is still suboptimal. The full therapeutic abilities of available drugs are reduced by medication, patient non-compliance, and side effects. Nanoparticles are expected to address these problems by providing a novel drug delivery approach for the treatment of PAH. Drug-loaded nanoparticles for local delivery can optimize the efficacy and minimize the adverse effects of drugs. Prostacyclin (PGI2) analogue, PDE5 inhibitors, ERA, pitavastatin, imatinib, rapamycin, fasudil, and oligonucleotides-loaded nanoparticles have been reported to be effective in animal PAH models and in vitro studies. However, the efficacy and safety of nanoparticle mediated-drug delivery systems for PAH treatment in humans are unknown and further clinical studies are required to clarify these points.

AB - There are three critical pathways for the pathogenesis and progression of pulmonary arterial hypertension (PAH): the prostacyclin (prostaglandin I2) (PGI2), nitric oxide (NO), and endothelin pathways. The current approved drugs targeting these three pathways, including prostacyclin (PGI2), phosphodiesterase type-5 (PDE5) inhibitors, and endothelin receptor antagonists (ERAs), have been shown to be effective, however, PAH remains a severe clinical condition and the long-term survival of patients with PAH is still suboptimal. The full therapeutic abilities of available drugs are reduced by medication, patient non-compliance, and side effects. Nanoparticles are expected to address these problems by providing a novel drug delivery approach for the treatment of PAH. Drug-loaded nanoparticles for local delivery can optimize the efficacy and minimize the adverse effects of drugs. Prostacyclin (PGI2) analogue, PDE5 inhibitors, ERA, pitavastatin, imatinib, rapamycin, fasudil, and oligonucleotides-loaded nanoparticles have been reported to be effective in animal PAH models and in vitro studies. However, the efficacy and safety of nanoparticle mediated-drug delivery systems for PAH treatment in humans are unknown and further clinical studies are required to clarify these points.

KW - Endothelin

KW - Nitric oxide

KW - Prostaglandin I

KW - Pulmonary arterial hypertension

UR - http://www.scopus.com/inward/record.url?scp=85075433651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075433651&partnerID=8YFLogxK

U2 - 10.3390/ijms20235885

DO - 10.3390/ijms20235885

M3 - Review article

C2 - 31771203

AN - SCOPUS:85075433651

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 23

M1 - 5885

ER -